Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Study of BMX-010 Ointment in Adults With Atopic Dermatitis
NCT05491447Phase 2Terminated
- Sponsor
- BioMimetix
- Start
- Jan 2023
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BMX-010 in atopic dermatitis (AD) (4 arms), sponsored by BioMimetix. Primary endpoint: Change from Baseline in Eczema Area and Severity Index at 4 weeks. Started Jan 2023; status: terminated.
02
Drugs
BMX-010
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05491447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05491447.